Department of Biology, University of The Sciences in Philadelphia, Philadelphia, PA 19104, USA.
Oncol Rep. 2020 Sep;44(3):1013-1024. doi: 10.3892/or.2020.7681. Epub 2020 Jul 7.
Neuroblastoma is the most common inheritable, solid neoplasm in children found under the age of 7 and accounts for approximately 7% of childhood cancers. A common treatment that has been prescribed for over a decade is retinoid therapy [using all‑trans retinoic acid (RA)]. Treatment with this differentiating agent has been revealed to progress the cells from their stem‑cell state to a mature neuronal state gaining classical neuronal characteristics, including the suppression of proliferation. However, the molecular mechanism underlying the action of RA treatment remains to be elucidated. In the present study, a novel mechanism of RA‑induced differentiation via regulation of receptor tyrosine kinase‑like orphan receptor 1 (ROR1) is reported. ROR1 is overexpressed in neuroblastoma but significantly downregulated in mature differentiated neurons. Hence, it was hypothesized that RA may modulate ROR1 leading to differentiation and termination of cancerous properties. Immunoblotting revealed that following RA treatment, ROR1 levels initially increased then sharply decreased by 96 h. This was paired with synaptophysin, a mature neuron marker, sharply increasing concurrently, providing evidence of differentiation by 96 h. Investigation of the ROR1 pathway confirmed ROR1‑dependent downstream activation of the PI3K/AKT signaling axis, a growth pathway previously demonstrated to promote differentiation. Chromatin immunoprecipitation revealed an increase in RAR binding to the promoters of ROR1 and its endogenous ligand, Wnt5a. This research provided compelling evidence that RA is able to modulate the expression of ROR1 and Wnt5a to promote differentiation through the expression of synaptophysin. This data combined with the overarching data from the scientific community regarding proliferation and other proliferative factors in early‑stage neurons provides a more in‑depth model of the process of differentiation in neurons.
神经母细胞瘤是 7 岁以下儿童中最常见的遗传性实体肿瘤,约占儿童癌症的 7%。十多年来,一种常见的治疗方法是类视黄醇治疗[使用全反式维甲酸(RA)]。使用这种分化剂的治疗已被证明可以使细胞从干细胞状态进展到成熟神经元状态,获得经典的神经元特征,包括抑制增殖。然而,RA 治疗作用的分子机制仍有待阐明。在本研究中,报道了一种通过调节受体酪氨酸激酶样孤儿受体 1(ROR1)来诱导 RA 诱导分化的新机制。ROR1 在神经母细胞瘤中过度表达,但在成熟分化的神经元中显著下调。因此,假设 RA 可能调节 ROR1 导致分化和终止癌症特性。免疫印迹显示,RA 处理后,ROR1 水平最初升高,然后在 96 小时急剧下降。这与突触小体素(一种成熟神经元标志物)同时急剧增加相匹配,96 小时时提供了分化的证据。对 ROR1 途径的研究证实了 ROR1 依赖性下游 PI3K/AKT 信号轴的激活,该生长途径先前被证明可促进分化。染色质免疫沉淀显示 RAR 与 ROR1 及其内源性配体 Wnt5a 的启动子结合增加。这项研究提供了令人信服的证据,表明 RA 能够通过调节 ROR1 和 Wnt5a 的表达来促进分化,从而表达突触小体素。这一数据结合科学界关于早期神经元中增殖和其他增殖因子的总体数据,提供了神经元分化过程的更深入模型。